Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Department of Medical Physics and Radiology, Faculty of Paramedical Sciences, Kashan University of Medical Sciences, Kashan, Iran.
Anticancer Agents Med Chem. 2020;20(6):636-642. doi: 10.2174/1871520620666200128112558.
In the current study, a systematic search and meta-analysis were performed to evaluate the effect of prostate cancer radiotherapy on testosterone levels of patients.
To illuminate the effect of radiotherapy on the testosterone level of prostate cancer patients, a systematic search was conducted in accordance with the PRISMA guideline in electronic databases of Scopus, Embase, PubMed, Web of Science, and clinical trials up to December 2018 using relevant keywords. Based on a certain set of inclusion and exclusion criteria, 12 eligible studies that had data on the testosterone level following prostate cancer radiotherapy were included in the meta-analysis.
According to the various techniques of prostate cancer radiotherapy, the dose values scattered to the testicular tissues ranged from 0.31 to 10 Gy. Combining the findings from 12 studies, it was found that prostate cancer radiotherapy leads to a significant reduction in the testosterone level (Weighted Mean Difference [WMD]: -51.38 ng/dL, 95% CI: -75.86, -26.90, I2=0.0%, P<0.05). Furthermore, subgroup analysis by the patient number showed a significant reduction in the testosterone level at patient number < 50 (WMD: -80.32 ng/dL, 95% CI: -125.10, -35.55, I2= 0.0%) and 50 < patient number < 100 (WMD: -46.99 ng/dL, 95% CI: - 87.15, -6.82, I2= 0.0%). Subgroup analysis based on treatment technique type revealed a significant reduction in testosterone level after conventional radiotherapy (WMD: -56.67, 95% CI: -100.45,-12.88, I2= 34.3%) and IMRT/SBRT technique (WMD: -57.42, 95% CI: -99.39, -15.46, I2= 0.0%) in comparison with the proton therapy (WMD: 0.00, 95% CI: -80.24, 80.24).
The findings showed a significant decrease in the testosterone level of prostate cancer patients after radiotherapy compared with pre-treatment levels.
在目前的研究中，我们进行了系统的检索和荟萃分析，以评估前列腺癌放疗对患者睾酮水平的影响。
为了阐明放疗对前列腺癌患者睾酮水平的影响，我们根据 PRISMA 指南，在 Scopus、Embase、PubMed、Web of Science 和临床试验电子数据库中，使用相关的关键词进行了系统搜索，检索时间截至 2018 年 12 月。根据一定的纳入和排除标准，我们纳入了 12 项符合条件的研究，这些研究的数据涉及前列腺癌放疗后的睾酮水平。
根据前列腺癌放疗的不同技术，散射到睾丸组织的剂量值范围从 0.31 到 10 Gy。综合 12 项研究的结果发现，前列腺癌放疗会导致睾酮水平显著下降（加权均数差[WMD]：-51.38ng/dL，95%CI：-75.86，-26.90，I2=0.0%，P<0.05）。此外，按患者数量进行的亚组分析显示，在患者数量<50 时（WMD：-80.32ng/dL，95%CI：-125.10，-35.55，I2=0.0%）和 50<患者数量<100 时（WMD：-46.99ng/dL，95%CI：-87.15，-6.82，I2=0.0%），睾酮水平也有显著下降。基于治疗技术类型的亚组分析显示，常规放疗（WMD：-56.67，95%CI：-100.45，-12.88，I2=34.3%）和 IMRT/SBRT 技术（WMD：-57.42，95%CI：-99.39，-15.46，I2=0.0%）与质子治疗（WMD：0.00，95%CI：-80.24，80.24）相比，患者的睾酮水平也有显著下降。
与治疗前相比，前列腺癌患者在放疗后睾酮水平显著下降。
